• Harmful mutations of the BRCA genes interfere with the protective function of these tumour suppressor genes, thus rendering the individual at higher risk of developing breast and other cancers.
  • BRCA1 and BRCA2 are inherited in an autosomal dominant manner.
  • Estimated lifetime risks
Tumour type Population risk BRCA1 BRCA2
Female breast 12% 60-90% 45-85%
Ovarian 1.4% 40-60% 10-30%
Male breast 0.1% 0.1-1% 5-10%
Prostate 10% 10% 20-25%
  • In primary care:-
    • Do not actively seek to find persons with a family history of breast cancer
    • First and second degree family history for those that present with concerns
    • If clinically relevant take family history for those over 35 on combined OCP or considering HRT
    • Second degree family history should include paternal and maternal relatives
    • For referral decisions be as accurate as possible with:-

      • Age of diagnosis
      • Tumour sites
      • Multiple cancers in an individual (including bilateral breast)
      • Jewish ancestry (5-10 x more likely to carry BRCA mutation)
      • NICE suggests that information that should be given to all patients presenting with concerns
  • Depending on their individual risk calculation patients may be offered:-
  1. A change in their breast screening program
  2. Prophylactic surgery
  3. Chemoprevention
  4. Genetic testing
  5. Lifestyle advice
  • GPs in Wales may be asked to initiate chemoprophylaxis with Tamoxifen (premenopausal women) or Raloxifine or Tamoxifen (postmenopausal women). This therapy is endorsed by NICE but off licence.
  • Chemoprophylaxis carries risks as well as benefits and the prescriber should be aware of these factors



Your privacy

This website uses cookies to ensure you get the best experience, please accept these so we can deliver a more reliable service.

To find out more, read our privacy policy and cookie policy.

Manage preferences